LPCN – lipocine inc. (US:NASDAQ)
Stock Stats
News
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone [Yahoo! Finance]
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) [Yahoo! Finance]
Form 4 Lipocine Inc. For: Dec 18 Filed by: Patel Mahesh V.
Form 4 Lipocine Inc. For: Dec 18 Filed by: Fogarty Krista
Form 8-K Lipocine Inc. For: Dec 15
Form 8-K Lipocine Inc. For: Dec 12
Form 8-K Lipocine Inc. For: Dec 08
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.